Payment overview · 2025
General Payments
$249.33
11 reported records · 10 companies
Healthcare provider profile · identity verified
Sergio Collazo, MD
Allopathic & Osteopathic Physicians|General Practice · TAMPA, FL · NPI 1619531027
Verified facts
What the public records show
CMS Open Payments records show Sergio Collazo, MD received $249.33 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.92 | 19.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.23 | 13.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.34 | 12.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.89 | 8.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.66 | 8.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.22 | 8.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.46 | 7.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.05 | 7.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.86 | 7.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.70 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $249.33 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.12 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.92 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 64 |
| Lisinopril | Lisinopril | 197 | 56 |
| Omeprazole | Omeprazole | 180 | 46 |
| Metformin Hcl | Metformin Hcl | 175 | 60 |
| Alprazolam | Alprazolam | 166 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 47 |
| Simvastatin | Simvastatin | 129 | 36 |
| Montelukast Sodium | Montelukast Sodium | 128 | 26 |
| Gabapentin | Gabapentin | 121 | 39 |
| Famotidine | Famotidine | 108 | 37 |
| Losartan Potassium | Losartan Potassium | 107 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 17 |
| Carvedilol | Carvedilol | 74 | 28 |
| Meloxicam | Meloxicam | 74 | 24 |
| Ibuprofen | Ibuprofen | 73 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 19 |
| Clonazepam | Clonazepam | 62 | 11 |
| Trazodone Hcl | Trazodone Hcl | 59 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 16 |
| Furosemide | Furosemide | 56 | 17 |
| Glipizide | Glipizide | 54 | 15 |
| Alendronate Sodium | Alendronate Sodium | 53 | 14 |
| Farxiga | Dapagliflozin Propanediol | 52 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 47 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 35 |
| Temazepam | Temazepam | 47 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Lorazepam | Lorazepam | 46 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 45 | 16 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 15 |
| Allopurinol | Allopurinol | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Ozempic | Semaglutide | 35 | 12 |
| Enalapril Maleate | Enalapril Maleate | 34 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 23 |
| Prednisone | Prednisone | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Eliquis | Apixaban | 30 | 12 |
| Methocarbamol | Methocarbamol | 30 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 12 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 12 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 16 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $249.33 · 11 records | Novo Nordisk Inc | Cologuard Collection Kit, ELIQUIS, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error